Blogs

Don't forget your second dose of Influenza vaccine

Submitted by Doctors on Sat, 01/16/2016 - 22:29

Infants and Children who have recieved  their  first dose of Influenza Vaccine this year requre a booster dose 1-2 months later.    

Important Allerject Recall October 28,2015

Submitted by Doctors on Thu, 10/29/2015 - 02:59

Sanofi Canada Issues Voluntary Nationwide Recall of Allerject® 
Due to Potential Inaccurate Dosage Delivery

 

 

 

FOR IMMEDIATE RELEASE

 

Laval, Quebec – October 28th, 2015 - Sanofi-aventis Canada Inc. (Sanofi Canadais recalling all Allerject® (epinephrine injection, USP). The voluntary recall involves all Allerject currently on the market and includes both the 0.15 mg/ 0.15 mL and 0.3 mg/0.3 mL strengths for hospitals, retailers and consumers. The products have been found to potentially have inaccurate dosage delivery.

If a patient who is experiencing a serious allergic reaction (i.e., anaphylaxis) did not receive the intended dose, there could be significant health consequences, including death because anaphylaxis is a potentially life-threatening condition.

 

As of October 26, 2015, Sanofi US and Canada have received 26 reports of suspected device malfunctions from an estimated 2,784,000 units distributed in North America. 

 

Specifically, in Canada, 9 suspected device malfunctions were reported out of an estimated 492,000 units distributed. None of these device malfunction reports have been confirmed. In these reports, patients have described symptoms of the underlying hypersensitivity reaction. No fatal outcomes have been reported among these cases.  

   

Allerject (epinephrine injection, USP) is used to treat life-threatening allergic reactions (anaphylaxis) in people who are at risk for or have a history of these reactions. All Allerject units are being recalled.

 

                                                <image002.jpg>          <image003.jpg>

 

Sanofi Canada is proactively communicating with wholesalers, pharmacists, patients and caregivers, patient associations, and hospitals to inform them of this precautionary voluntary recall and how to proceed.

 

Sanofi Canada is actively working with suppliers of alternative epinephrine auto-injectors to have a full stock available in Canada as soon as possible.  

 

Canadian customers are asked to immediately return the product to their local pharmacy to obtain an alternate epinephrine auto-injector. In the absence of availability of an alternate epinephrine auto-injector, patients are instructed to retain their Allerject device until an alternate auto-injector is available.

 

In light of the need to manage supply associated with this recall, we are asking customers and pharmacists to limit the replacement of Allerject to one unit or the appropriate number of units as instructed by your healthcare professional until full alternative stock is available. 

 

If patients are unable to obtain supplies of alternative epinephrine auto-injectors, and in the event of a life-threatening allergic reaction (anaphylaxis), patients who do not have a replacement product should use their Allerject device, call 911 and immediately seek emergency medical services, in accordance with current product labelling.

 

Sanofi Canada is committed to patient safety and the quality of Allerject, and will continue to work closely with our partners and regulatory authorities to resolve this issue in a timely manner.

 

Any questions or concerns regarding this voluntary product recall, please contact the Allerject Call Center at 1-855-405-4321.

 

Any adverse events that may be related to the use of these products should be reported either to:

 

Sanofi Canada

Phone:             1-855-405-4321

 

Health Canada

Phone:             1-866-234-2345

 

MedEffect Canada website: 

http://www.hc-sc.gc.ca/dhp-mps/medeff/report-declaration/index-eng.php

 

This recall is being conducted with the knowledge of Health Canada.

 

Important Safety Information
Indication

 

Allerject® is indicated for the emergency treatment of anaphylactic reactions in patients who are determined to be at increased risk for anaphylaxis, including individuals with a history of anaphylactic reactions.

 

Vaccinations for teenagers - Meningococcal ACWY booster age 17

Submitted by Doctors on Fri, 08/14/2015 - 05:15

Meningococcal ACWY  (Menactra/Menveo)  is given to Ontario teenagers at no cost in grade 7 .  Invasive  Meningococcal Disease (IMD) is an important cause of sudden onset bacterial blood infections (Septicemia)  leading to Meningitis , disability and death.    IMD mortality is approximately 10%.  Of  IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations Teenagers  and young adults are high risk age groups for this bacterial infection.   

The Centre for Disease  control  recommends a dose of Menactra/Menveo to be given in Grade 7 and  a booster dose in Grade 12 to  boost immunity post secondary school .  We agree and recommend a second  dose of Menactra/Menveo as a booster in Grade 12.  It is not covered by OHIP and is available for a fee at our office. 

Please  call our office and book an appointment  to recieve  a Meningococcal ACWY (Menactra/Menveo) booster.

 

-return to Vaccination for teenagers - our recommendations-

Vaccinations for Teenagers - age 15 and older Meningococcal B

Submitted by Doctors on Fri, 08/14/2015 - 05:08

Invasive Meningococcal Disase (IMD) is an important cause of death and disability for which teenagers and young adults are at particular risk.  IMD mortality is approximately 10%.  Of  IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations .  In Canada, IMD is caused by the two most prominent strains -  B and C strains.   Other vaccine preventable strains are A, W and Y strains.  

Meningococcal ACWY (Menactra/Menveo) is given to Ontario teenagers at no cost in grade 7.   We also encourage a booster of Meningococcal ACWY   in grade 12.  

Meningococcal B vaccine (Bexsero) Is recomenneded to prevent IMD caused by B strain  which is the most common strain leading to IMD in Canada.     We  encourage immunization against Meningococcal B strain to all teenagers age 15  and older.  It is not currently paid for by OHIP  and is available for private purchase in our office.    

Please call our office to book an appointment to recieve Meningococcal B vaccine

-return to Vaccination for teenagers - our recommendations-

 

 

 

 

Vaccinatons for teenagers - age 14 dTaP

Submitted by Doctors on Fri, 08/14/2015 - 04:53

All Canadian teenagers are required to prove immunization with dTaP.  It provides booster coverage to immunizations typically recieved 10 years previously- Diptheria, Tetanus and Pertussis (Whooping Cough) .   It is given in all physicians offices along with the 14 year old checkup.    

-return to Vaccination for teenagers - our recommendations-

 

Vaccinations for Teenagers -HPV

Submitted by Doctors on Fri, 08/14/2015 - 04:45

 

HPV is a virus that is transmitted via sexual intercourse and other sexual behaviours.    It occurs  in males and females and is the commonest sexually transmitted  disease in Canada.  HPV  causes genital warts in males and females. It causes Cancer of the Cervix in females , as well as other  cancers of the genitals  and anus in males and females.   It causes cancers of the mouth and throat and head and neck in males and females. Once someone catches HPV there is no cure for it. 

HPV vaccines are recommended for males and females age 9 and over  .  In Ontario Gardisil is given by school public health nurses  to Ontario school boys and girls in grade  7 and to girls in grade 8 at no  cost .  It prevents 2 wart causing strains and 2 of the commonest cancer causing strains.   At present Ontario school boys in grade 8 and above are not given Gardisil via a school vaccination program and must purchase it privately.  

Recently Gardisil-9 has been released for  improved coverage of cancer causing strains of  HPV .  It prevents the same 2 wart causing strains and the 7 commonest cancer  causing strains of HPV.    It is not  covered by OHIP and can be purchased privately in our office.    

The Society of Obstetricians and Gynecologists of Canada (SOGC) recommends HPV vaccination using Gardisil-9 for all Canadians in the at risk age groups  

Please note that Ontario school girls  and boys will be offered Gardisil during the 2016-2017 school year  and not Gardisil-9 which has improved coverage.  We encourage all families to consider recieving  Gardisil-9  as we feel it is a better vaccine with improved coverage.    Please notify our office if you wish to recieve Gardisil-9 vaccination 

-return to Vaccination for teenagers - our recommendations-

 

 

Vaccinations for teenagers - Grade 7 Students Hepatitis B and Menactra

Submitted by Doctors on Wed, 08/12/2015 - 04:49

Grade 7 vaccines:   Hepatitis B and  Meningococcal A,C,W,Y  (Menactra/Menveo)   These vaccines are given during the school year by public  health nurses at Ontario schools.   

Hepatitis B  is given to students who have not had Hepatitis B vaccine previously.   If  he or she has  recieved 3  doses of Hepatitis B vaccine  or  3  doses of Twinrix (Hepatitis A and B) vaccine then he or she wont need  the vaccine givin in grade 7.   Hepatitis B is a disease that leads to jaundice and chronic liver  disease in some patients.  It is transmitted  through blood products and body fluids.  It is highly recommended that teenage people be up to date with Hepatitis B vaccination 

Meningococcal ACWY  (Menactra/Menveo)  is given to Ontario teenagers at no cost in grade 7 .  Invasive  Meningococcal Disease (IMD) is an important cause of sudden onset bacterial blood infections (Septicemia)  leading to Meningitis , disability and death.    IMD mortality is approximately 10%.  Of  IMD survivors 10-20% have long term sequelae including hearing loss, neurologic disabilities and digit or limb amputations Teenagers  and young adults are high risk age groups for this bacterial infection.   

The Centre for Disease  control  recommends a dose of Menactra/Menveo to be given in Grade 7 and  a booster dose in Grade 12 to  boost immunity post secondary school .  We agree and recommend a second  dose of Menactra/Menveo as a booster in Grade 12.  It is not covered by OHIP and is available for a fee at our office. 

-return to Vaccination for teenagers - our recommendations-

Vaccinations for teenagers - our recommendations

Submitted by Doctors on Wed, 08/12/2015 - 04:16

Vaccines  for adolescents need to kept up to date  and newer vaccine recommendations  are important for you to know about. This article will briefly indicate which vaccines are recommended  and then go into detail for each and why.   These assume that recommended vaccines up until age 4 to 6 years have been given previously.

Click on the links below for more information about each vaccine.

Grade 7:  Hepatits B and Menactra  given  in Ontario Schools during the school year

Grade 8: HPV/Gardasil given free of charge to Girls only in Ontario schools during the school year. Note recommendation for updated Gardisil 9 available for males and females  not covered by OHIP and available for a fee via  our office for teenage boys and girls age 10 and over 

Age 14: DPT Diptheria Pertussis Tetanus booster.  

Age 15+:  Meningococcal-b not covered by OHIP and availabe for a fee via our office

Grade 12: Menactra booster is not covered by OHIP and availabe for a fee via our office    

 

 

 

We're on Social Media

Submitted by Doctors on Sun, 07/19/2015 - 22:41

Like us on Facebook or Follow us on Twitter to get important announcements, medical news  and updates.

Important information regarding seasonal flu vaccine

Submitted by Doctors on Wed, 10/22/2014 - 01:10

Important information regarding seasonal flu vaccine can be accessed via the following link :

              http://www.health.gov.on.ca/en/pro/programs/publichealth/flu/uiip/uiip_f...